pan-HDAC inhibitors approved by FDA to treat CTCL, PTCL, AML:Vorinostat (SAHA),Belinostat (PXD-101),Panobinostat (LBH589),Pracinostat (MEI pharma),Romidepsin (FK228)Chidamide (CS055, HBI-8000)pan-HDAC inhibitors are being evaluated clinically:Resminostat (4SC-201) →for Hodgkin’s lymphoma;Givinostat (ITF2357) →for polycythemia;Quisinostat (JNJ-26481585), Entinostat and Mocetinostat →for various cancers.pan-HDAC inhibitor in preclinical stage: Trigustatin A. This evidence concerns the gene HDAC9 and Hodgkins lymphoma.